Search

Your search keyword '"Papagudi G Subramanian"' showing total 3 results
Start Over Author "Papagudi G Subramanian" Topic immunophenotyping
3 results on '"Papagudi G Subramanian"'

1. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies

Author

Prashant R, Tembhare, Sitaram, Ghogale, Wilma, Tauro, Yajamanam, Badrinath, Nilesh, Deshpande, Shweta, Kedia, Keziah, Cherian, Nikhil V, Patkar, Gaurav, Chatterjee, Sumeet, Gujral, and Papagudi G, Subramanian

Subjects
Adult, Aged, 80 and over, Male, Plasma Cells, Paraproteinemias, Middle Aged, Flow Cytometry, Immunophenotyping, Bone Marrow, Signaling Lymphocytic Activation Molecule Family, Case-Control Studies, Humans, Female, Immunoglobulin Light Chains, Biomarkers, Aged
Abstract

Current flow-cytometric plasma cell (PC) gating is based on CD138, CD38, and CD45 expression. CD138 is known for variable expression and loss during storage and processing. Introduction of anti-CD38 and anti-CD138 monoclonal-antibody therapies has limited the use of these markers during follow-up. Hence, additional reliable PC-gating markers are required. Recently, CD229 has been claimed as an alternative PC-gating marker. However, these studies are limited to a small cohort of samples. We evaluated the utility of CD229 as a new PC-gating marker in routine laboratory practice.Expression of CD229 was studied in 310 bone marrow (BM) samples (251 plasma-cell disorders and 59 controls) and compared with CD138 and CD38 expression. We also evaluated the effect of additional processing for cytoplasmic immunoglobulin-light-chains (CyIgL) staining on the quantitation of PC.Expression of CD229 was consistently stronger on PC than other hematopoietic-cells (p 0.001). PC-percentages using CD229 in combination with CD38 or CD138 and CD45 revealed high correlation with a reference gating-strategy using CD138, CD38 and CD45 (r = 0.98, r = 0.99 r = 0.99 respectively) and r = 0.92 using CD229 and CD45 without CD38 or CD138. In contrast, CD138 expression showed significant variability (CV-MFI, 97.5) and loss from PC in 53% of samples. Quantitation of PC was found to be lower in 69.3% and higher in 30.7% samples processed for CyIgL-staining as compared to surface-staining.CD229 is a reliable new alternative PC-gating marker in routine laboratory practice. Quantitation of PC based on CD138 expression or from samples processed for CyIgL-staining should be used with caution. © 2018 International Clinical Cytometry Society.

Published
2017

2. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000

Author

Prashant R, Tembhare, Sitaram, Ghogale, Nisha, Ghatwai, Yajamanam, Badrinath, Nikesh, Kunder, Nikhil V, Patkar, Asma R, Bibi, Gaurav, Chatterjee, Brijesh, Arora, Gaurav, Narula, Shripad, Banawali, Nilesh, Deshpande, Prathibha, Amare, Sumeet, Gujral, and Papagudi G, Subramanian

Subjects
Adult, Male, B-Lymphocytes, Neoplasm, Residual, Adolescent, Infant, Flow Cytometry, GPI-Linked Proteins, Immunophenotyping, Young Adult, Bone Marrow, Child, Preschool, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Biomarkers, Tumor, Humans, Female, B7-2 Antigen, Child, 5'-Nucleotidase
Abstract

Multiparametric flow cytometry (MFC) is a popular technique for minimal residual disease (MRD) analysis. However, its applicability is still limited to 90% of B-cell precursor acute lymphoblastic leukemia (BCPALL) due to two major issues, i.e. a proportion of cases do not express adequate leukemia associated immunophenotype (LAIPs) with currently used markers and drug-induced antigen modulation. Hence, the incorporation of additional reliable markers is required for the further improvement of MFC-based MRD evaluation. We studied the utility of new markers in improvising MFC-based MRD detection in BCPALL.Expression-patterns of six new markers, i.e. CD24, CD44, CD72, CD73, CD86, and CD200 were studied in leukemic-blasts from ninety childhood BCPALL patients and in hematogones from 20 uninvolved staging bone marrow (BM) and ten postinduction non-BCPALL BM samples using eight-color MFC. The utility of these new markers in the day 35 postinduction MRD evaluation was determined.Frequencies of LAIPs of CD73, CD86, CD72, CD44, CD200, and CD24 in diagnostic samples were 76.7, 56.7, 55.6, 50, 28.9, and 20%, respectively. Differential expression of all new markers was highly significant (P 0.01) between early (CD10+ CD19+ CD34+) hematogones, late (CD10+ CD19+ CD34-) hematogones and BCPALL blasts except between early hematogones and BCPALL blasts for CD200 (P = 0.1). In MRD-positive samples, CD73 showed the maximum (83%) frequency of LAIP and CD86 showed the highest (100%) stability of aberrant expression. Inclusion of CD73 and CD86 increased the applicability of MFC-MRD assay to 98.9% MRD samples.CD73 and CD86 are the most relevant markers to incorporate in the routine MRD evaluation of BCPALL. © 2016 International Clinical Cytometry Society.

Published
2016

3. Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin’s Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India

Author

Prashant R. Tembhare, Gaurav Chatterjee, Anumeha Chaturvedi, Niharika Dasgupta, Twinkle Khanka, Shefali Verma, Sitaram G. Ghogale, Nilesh Deshpande, Karishma Girase, Manju Sengar, Bhausaheb Bagal, Hasmukh Jain, Dhanalaxmi Shetty, Sweta Rajpal, Nikhil Patkar, Tushar Agrawal, Sridhar Epari, Tanuja Shet, Papagudi G. Subramanian, and Sumeet Gujral

Subjects
immunophenotyping, T cell, non-Hodgkin’s lymphoma, real-world practice, flow cytometry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundT-cell/NK-cell non-Hodgkin’s lymphoma (T/NK-NHL) is an uncommon heterogeneous group of diseases. The current classification of T/NK-NHL is mainly based on histopathology and immunohistochemistry. In practice, however, the lack of unique histopathological patterns, overlapping cytomorphology, immunophenotypic complexity, inadequate panels, and diverse clinical presentations pose a great challenge. Flow cytometric immunophenotyping (FCI) is a gold standard for the diagnosis, subtyping, and monitoring of many hematological neoplasms. However, studies emphasizing the role of FCI in the diagnosis and staging of T/NK-NHL in real-world practice are scarce.MethodsWe included T-cell non-Hodgkin’s lymphoma (T-NHL) patients evaluated for the diagnosis and/or staging of T/NK-NHL using FCI between 2014 and 2020. We studied the utility of FCI in the diagnosis and subtyping of T/NK-NHL and correlated the FCI findings with the results of histopathology/immunohistochemistry. For correlation purposes, patients were categorized under definitive diagnosis and subtyping, inadequate subtyping, inadequate diagnosis, and misdiagnosis based on the findings of each technique.ResultsA total of 232 patients were diagnosed with T/NK-NHL. FCI findings provided definitive diagnoses in 198 patients and subtyping in 187/198 (95.45%) patients. The correlation between FCI and histopathological/immunohistochemistry results (n = 150) demonstrated an agreement on the diagnosis and subtyping in 69/150 (46%) patients. Of the remaining cases, the diagnosis and subtyping were inadequate in 64/150 (42.7%), and 14/150 (9.33%) were misdiagnosed on histopathology/immunohistochemistry results. FCI provided definitive diagnosis and subtyping in 51/64 (79.7%) patients. Among these, 13 patients diagnosed with peripheral T-cell lymphoma not-otherwise-specified were reclassified (angioimmunoblastic T-cell lymphoma (AITL)-11 and prolymphocytic leukemia-2) on FCI. It corrected the diagnosis in 14 patients that were misdiagnosed (6 B-cell NHL (B-NHL), 3 Hodgkin’s lymphoma, 1 acute leukemia, and 1 subcutaneous panniculitis-like T-cell lymphoma) and misclassified (3 T-NHL) on histopathological results. AITL was the commonest T-NHL misclassified on histopathological results. FCI also confirmed the definite involvement in 7/83 (8.4%) and 27/83 (32.5%) bone marrow (BM) samples reported as suspicious and uninvolved, respectively, on histopathological evaluation.ConclusionAITL was the most frequently diagnosed T/NK-NHL in this study. FCI provided a distinct advantage in detecting BM involvement by T/NK-NHL, especially in patients with low-level involvement. Overall, our study concluded that FCI plays a critical role in the diagnosis, subtyping, and staging of T/NK-NHL in real-world practice.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results